Skip to search formSkip to main contentSkip to account menu

vicriviroc

A piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. Vicriviroc is designed to bind to CCR5 and inhibit… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Timothy J. Henrich, Nicolas R. P. Lewine, Sun-Hee Lee, Suhas S. P. Rao, Reem Berro, Roy M. Gulick, John P. Moore, Athe M. N… 
2011
2011
C-C chemokine receptor 5 (CCR5) is a clinically proven target for inhibition of HIV-1 infection and a potential target for… 
2010
2010
[¹¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[¹⁸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11… 
2009
2009
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2008
2008
Vicriviroc is an investigational CCR5 inhibitor that seemed promising in industry-funded, phase I clinical trials involving… 
2007
2007
Vicriviroc is one of two CCR5 inhibitors being developed to treat HIV infection. In this phase II study (ACTG 5211… 
Review
2007
Review
2007
In the context of emerging resistance to antiretroviral agents in HIV medicine, the development of new drugs classes with a novel… 
2006
2006
s (91, 92, 293). A European group (abstract 33LB) demonstrated in the first randomized controlled trial that active herpes…